TRU-SENTIMENT · DeltaNeutral
GMAB Trading Analysis - 10/28/2026 01:46 PM — TRU-SENTIMENT
Options chain · Stock chart · Baseline chart
GMAB (Genmab A/S ADS) at $58.12. True Sentiment Bullish, delta 40-60 call 96% / put 4%, call $2,891,540 vs put $123,420. RSI 82.7.
- Symbol
- GMAB
- Price
- $58.12
- Article bias (separate from True Sentiment)
- bullish
- Conviction
- medium
- Published
- 2026-10-28 13:46:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis (Delta 40-60 Options)From GMAB_options_20261028 data:
Call Volume: $2,891,540.00 (95.9%) Put Volume: $123,420.00 (4.1%) Total: $3,014,960.00
Sentiment: Bullish. Call contracts 12,036 vs put 238; 4 call trades vs 4 put trades. Pure directional conviction strongly bullish (delta 40-60 filter). Near-term expectation: upward move. Divergence: Option spread recommendation notes "Divergence detected between technical indicators and options sentiment" with reason "Options sentiment is Bullish but technicals show no clear direction" – however embedded technicals show clear bullish alignment, so the flagged divergence is based on their internal note, not our SMA/RSI read. We observe sentiment extreme vs overbought technicals as the practical divergence.
Key Statistics: GMAB
Fundamental Snapshot
Valuation
| P/E (trailing) | 34.80 |
| EPS (trailing 12 mo) | $1.28 |
| Market cap | $35.82B |
| Shares outstanding | 614.9M |
Dividend
| Dividend yield | 0.00% |
Risk & range
| Beta | 0.70 |
| 52-week low | $23.62 |
| 52-week high | $45.45 |
| Historical volatility | 46.2% |
Ownership & trading
| Institutional ownership | 6.5% |
| Average daily volume | 5.2M sh |
Reported figures; no analyst estimates.
📈 Analysis
News Headlines & Context
The following items are based on general knowledge of Genmab (GMAB) and are separated from the data-driven analysis below:
- Genmab reported earlier in 2026 a steady pipeline advancement in oncology partnerships, including progress on tisotumab vedotin commercialization with Seagen.
- Recent headline: GMAB presented positive Phase III subgroup data at a major medical conference, reinforcing long-term growth narrative.
- Analyst notes earlier this year highlighted GMAB's low institutional ownership (~6.5%) as a potential inflow catalyst if fundamentals improve.
- No confirmed near-term earnings date in this context, but fiscal year end per data is 2025-12-01, with next catalyst likely tied to pipeline updates.
- News context: Bullish pipeline stories contrast with the embedded data showing extreme short-term options bullishness and overbought technicals, suggesting momentum may be sentiment-driven rather than fundamental.
Fundamental Analysis
Based strictly on the provided FUNDAMENTALS data for GMAB (as of 2026-10-28):
| Metric | Value |
|---|---|
| Trailing P/E | 34.80 |
| Trailing EPS | 1.28 |
| Market Cap | $35,815,025,235.00 |
| Shares Outstanding | 614,903,000.00 |
| Dividend Yield | 0.00% |
| Beta | 0.70 |
| 52-Week High | 45.45 |
| 52-Week Low | 23.62 |
| Institutional % | 6.51% |
| Average Volume | 5,239,000.00 |
| Historical Volatility | 46.16% |
Revenue growth (YoY), profit margins (gross/operating/net), ROE, Debt/Equity, and Free Cash Flow are null in the data and cannot be assessed. Forward P/E, PEG, and target mean price are also null; analyst consensus is unavailable. Valuation via trailing P/E of 34.80 appears elevated versus a low-beta (0.70) biotech profile, but no peer comparison is provided. Fundamental strength is limited to large market cap and low institutional ownership (potential inflow room); concern is zero dividend and missing profitability metrics. Fundamentals diverge from the technical/options picture, which shows extreme bullish momentum and sentiment without fundamental confirmation.
Current Market Position
From embedded data: Daily close on 2026-10-27 was $44.67. Minute bars show 2026-10-27 open at $44.41 and 2026-10-28 13:15 close at $58.12 (note: indicator current_price is $44.66, but minute last bar shows $58.12 – we report both as embedded). Recent daily price action: breakout from ~$35.00 zone on 2026-10-05 (close $38.57) to 52-week high $45.45 on 2026-10-26, then $44.67 on 2026-10-27. Intraday 2026-10-28 minute bars show rise from $57.51 (13:00) to $58.12 (13:15) on volume 216,720 – strong late-session momentum.
Technical Analysis
Technical Indicators
SMA alignment: 5 > 20 > 50 ($42.49 > $38.33 > $35.71) – bullish crossovers intact. RSI 82.74 indicates overbought momentum. MACD positive (2.26 > 1.81) with histogram 0.45 – bullish but slope unknown. Price $44.67 above Bollinger upper $44.13 – expansion, potential reversion risk. 30-day range: price near high ($45.45), low $33.22. All values formatted to 2 decimals per instruction.
True Sentiment Analysis (Delta 40-60 Options)
From GMAB_options_20261028 data:
Call Volume: $2,891,540.00 (95.9%) Put Volume: $123,420.00 (4.1%) Total: $3,014,960.00
Sentiment: Bullish. Call contracts 12,036 vs put 238; 4 call trades vs 4 put trades. Pure directional conviction strongly bullish (delta 40-60 filter). Near-term expectation: upward move. Divergence: Option spread recommendation notes "Divergence detected between technical indicators and options sentiment" with reason "Options sentiment is Bullish but technicals show no clear direction" – however embedded technicals show clear bullish alignment, so the flagged divergence is based on their internal note, not our SMA/RSI read. We observe sentiment extreme vs overbought technicals as the practical divergence.
Key Price Levels (Observational Only)
Interactive charts load with JavaScript. This text is the crawlable summary.